OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Full Issue PDF	130
Priorities in Cardio-Oncology	127
Cardiovascular Safety in Oncology Clinical Trials	113
Balancing Promise and Evidence	100
Hormonal Therapy and Cardiovascular Health	98
Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors	82
Full Issue PDF	74
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	74
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	72
Epigenomics of Cardio-Oncology	72
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	63
Atrial Fibrillation in Patients With Cancer	61
Full Issue PDF	60
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	59
Editorial Board	59
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	55
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	55
Full Issue PDF	55
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	52
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	50
Full Issue PDF	50
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	47
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	43
Frailty	42
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	41

Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	40
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	39
Cardiac Risk Stratification Before Lung Cancer Radiation	37
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	37
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	34
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	34
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	33
Editorial Board/Officers Page	33
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	32
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	32
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	32
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	31
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	31
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	29
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	26
Cancer Immunotherapy Beyond Checkpoint Blockade	26
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	26
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	26
Full Issue PDF	25
Permissive Cardiotoxicity	25
Reply	24
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	24
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	24
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	23
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	23
Quality-of-Care Measures for Cardio-Oncology	23
Leveling Up	23
Developing a Model for Cross-Institutional Educational Collaborations	23
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	23
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	22
Endothelin-1	22
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	22
Editorial Board	22
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	21
Vascular Complications of Atrial Fibrillation in Patients With Cancer	21
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	21
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	21
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy	20
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	20
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	20
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	20
CHA2DS2-VASc Score in Cardio-Oncology	20
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	20
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	20
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	20
Fluoropyrimidine Therapy in Gastrointestinal Cancer	19
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	19
Diet and Prevention of Cardiovascular Disease and Cancer	18
Imaging Immune Checkpoint Inhibitor Myocarditis	18
High-Sensitivity Troponin I	18

Full Issue PDF	18
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	17
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	17
The United Kingdom’s First Cardio-Oncology Service	17
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	17
Low QRS Voltages in Cardiac Amyloidosis	17
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	17
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	17
To Adjudicate or Not Adjudicate	16
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	15
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	15
Cardiovascular Risk Assessment in Patients With Kidney Cancer	15
Cancer Therapy–Related Cardiac Dysfunction	15
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	15
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	15
Full Issue PDF	15
FULL ISSUE PDF	15
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	15
ABSTRACT WITHDRAWN	14
Author Index	14
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	14
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	13
How to Perform Hematopoietic Stem Cell Transplantation	13
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	13
Hearts on the Minds of Oncologists	13
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	12
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	12
Cardiovascular Care After Cancer	12
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	12
Navigating the Uncharted	12
Cardiovascular Considerations After Cancer Therapy	12
(Less) Time and Energy	12
Guiding Treatment With Recovered CTRCD	12
Reply	11
Reply	11
Reply	11
Clinical Practice Guidelines in Cardio-Oncology	11
Preventing Cancer Therapy–Related Cardiotoxicity	11
JACC: CardioOncology	11
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	11
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	11
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	11
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	11
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	11
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	10
Editorial Board/Officers Page	10
Addressing the Overlooked	10
Overcoming LGBTQI+ Disparities in Cardio-Oncology	10
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	10
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	10
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	10
Learning From Trials	10
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	10
Full Issue PDF	10
Reply	10
The Cause of Death in Patients With Cancer	10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	10
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	10
When Clot Is Tumor	10
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	10
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	9
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	9
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	9
Reply	9
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	9
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	9
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	8
Reply	8
Reply	8
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage	8
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	8
Editorial Board	8
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	8
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	8
Full Issue PDF	8
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	8
Reply	8
Assessing STEMI Outcomes in Patients With Cancer	8
The ESC Cardio-Oncology Guidelines	8